$1.41
N/A
Last update: Nov 10, 7:00 PM
Tvardi Therapeutics Inc
TVRDNASDAQ
The average analyst price target for Tvardi Therapeutics is $11.38, 695.8% above the current price. Of 10 analysts, 8 rate it Buy, 1 Hold and 1 Sell. Targets range from $3 to $39. The latest change came on Oct 20, 2026, when Chardan Capital initiated coverage of Tvardi Therapeutics with a Buy rating and a $8 price target.
Price Target Range — 6 Quarters
Analyst Consensus — 10 Analysts
Rating Trend — Last 9 Months
